Research on the peptide hormone amylin presents a paradox in Alzheimer's disease — some studies show it reduces brain amyloid and improves cognition, while others suggest it may contribute to the disease through protein misfolding and aggregation.
Pramlintide is already FDA-approvedThis amylin analog approved for diabetes shows potential to reduce brain amyloid and improve cognition in Alzheimer's models
What the researchers found
The review identifies a key paradox in amylin research for Alzheimer's disease. Multiple studies demonstrate that amylin and the amylin analog pramlintide (already FDA-approved for diabetes) can reduce amyloid burden in the brain and improve cognitive symptoms in Alzheimer's models.
However, contradictory evidence shows that amylin has a propensity to misfold and aggregate under certain conditions — similar to the amyloid-beta protein central to Alzheimer's pathology. This raises the possibility that amylin could contribute to, rather than treat, Alzheimer's disease. The author identifies several critical gaps including limited understanding of amylin system changes during aging, complexities of amylin receptor signaling, and how changing pathophysiology during AD progression might explain these conflicting results.
Why it matters
Alzheimer's disease affects over 50 million people worldwide and currently has no cure. The possibility that pramlintide — an already FDA-approved drug — could be repurposed for Alzheimer's treatment is exciting because it would bypass years of drug development. However, the conflicting evidence about amylin's role means we need to understand whether this peptide helps or harms before pursuing it as a treatment. Getting this wrong could potentially worsen the disease in patients.
How the study worked
This is a narrative review of the published literature examining both the beneficial and harmful roles of amylin in Alzheimer's disease. The author systematically evaluates preclinical and clinical evidence from both perspectives and identifies methodological factors and knowledge gaps that may explain contradictory findings in the field.
What this study cannot tell us
As a narrative review, the paper reflects the author's interpretation and selection of the literature rather than a systematic analysis. The conflicting evidence in the field itself is a major limitation — the same peptide showing both beneficial and harmful effects makes it difficult to draw definitive conclusions. Most evidence comes from animal models, with limited human clinical data on amylin's effects in Alzheimer's patients.
How to read the evidence
This is a narrative review that synthesizes preclinical and early clinical evidence. While it provides a comprehensive overview of the conflicting literature, the contradictory findings across studies mean the overall evidence for amylin as either a cause or treatment of Alzheimer's remains inconclusive.
When this study was published
Published in 2018, some of the knowledge gaps identified may have been partially addressed by subsequent research. The core paradox of amylin's dual role in Alzheimer's, however, remains an active area of investigation.
The bigger picture
This review sits at the intersection of two major research trends: peptide therapeutics and the metabolic-neurodegenerative disease connection. Growing evidence links diabetes and Alzheimer's (sometimes called 'type 3 diabetes'), and amylin is central to both conditions. Understanding amylin's dual nature could reshape how we think about the relationship between metabolic peptide hormones and neurodegeneration, potentially opening new therapeutic avenues beyond just amylin itself.
Questions still open
- Under what specific conditions does amylin act beneficially versus harmfully in the Alzheimer's brain?
- Could the timing of amylin-based treatment during Alzheimer's progression determine whether it helps or worsens the disease?
- Would modified amylin analogs that retain beneficial signaling but cannot misfold resolve the paradox?
Common questions
What is amylin and what does it normally do in the body?
How could the same peptide both help and harm Alzheimer's disease?
Read the original research
Amylin in Alzheimer's disease: Pathological peptide or potential treatment?
Neuropharmacology, 136(Pt B), 287-297
Citation
Mietlicki-Baase, Elizabeth G. (2018). Amylin in Alzheimer's disease: Pathological peptide or potential treatment?. Neuropharmacology, 136(Pt B), 287-297. https://doi.org/10.1016/j.neuropharm.2017.12.016